drugset / Trial / NCT00424710

Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)

NCT00424710

Phase 1 Completed 17 enrolled Hawaii Pacific Health Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.

Timeline

Start
2007-01
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal